GHR Antagonists (class)

The speaker references the work of Andrew Scoly, who developed Growth Hormone Releasing Hormone (GHRH) antagonists to treat cancer. While early cell culture studies suggested GHR agonists might increase cancer, in vivo research demonstrated that blocking GH signaling can work against tumors, validating the importance of context-dependent molecular pathways.